Details of the Drug Combinations

General Information of This Drug (ID: DM5DWMU)

Drug Name

Rimantadine DM5DWMU

Synonyms

Remantadine; Riamantadine; Rimant; Rimantadina; Rimantadinum; Enamine_005755; Alpha-Methyladamantanemethylamine; Flumadine (TN); Rimantadina [INN-Spanish]; Rimantadine (INN); Rimantadine [INN:BAN]; Rimantadinum [INN-Latin]; Alpha-Methyl-1-adamantanemethylamine; Rimant & .alpha. IFN; Rimantidine & .alpha.IFN; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-& IFN.alpha; 1-(1-Adamantyl)ethanamine; 1-(1-Adamantyl)ethylamin; 1-(1-adamantyl)-ethylamine; 1-(1-adamantyl)ethylamine; 1-(adamantan-1-yl)ethan-1-amine; 1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine; 1-Adamantan-1-yl-ethylamine; 1-Adamantan-1-ylethylamine; 1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine

Indication

Disease Entry	ICD 11	Status	REF
Influenza A virus infection	1E30	Approved	[1]
Influenza virus infection	1E30-1E32	Approved	[2]
Severe acute respiratory syndrome (SARS)	1D65	Investigative	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Antiviral Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Rimantadine + Panobinostat	DCCOCJ0	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Rimantadine + Idarubicin	DCJ7DTP	Idarubicin	Glioblastoma? (Cell Line: T98G)	[4]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019649.
2	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 076132.
3	In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004 Sep;31(1):69-75. doi: 10.1016/j.jcv.2004.03.003.
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.